Skip to main content
Publications
Castellsague J, Perez-Gutthann S , Calingaert B , Bui C , Varas-Lorenzo C, Arana A , Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany . Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):615-24. doi: 10.1002/pds.4167
Arana A , Varas-Lorenzo C, McQuay LJ, Ziemiecki R , Bui CL , Gilsenan AW , Rothman KJ , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Margulis AV , Perez Gutthann S . Do individual antimuscarinic drugs to treat overactive bladder have different cardiovascular risks? A UK CPRD cohort study . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):534-5.
Castellsague J, Calingaert B , Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Varas-Lorenzo C, Arana A , Bui C , Prados-Torres A, Gonzalez-Rubio F, Roso-Llorach A, Citarella A, Garbe E, Blenk T, Perez-Gutthann S . Characterization of new users of cilostazol in the United Kingdom, Spain, Sweden, and Germany . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):203-4.
Margulis A , Houben E, Olesen M, Hallas J, Overbeek J, Pottegard A, Ye W, Villegas D, Perez-Gutthann S , Arana A . Drug utilization study: evaluation of the use of nepafenac in the Netherlands and Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):225.
Margulis AV , Varas-Lorenzo C, Bui CL , McQuay LJ, Ziemiecki R , Reynolds M , Rebordosa C , Pladevall-Vila M , Fortuny J , Rivero-Ferrer E , Plana E , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS) . Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
Margulis AV , Linder M, Arana A , Pottegard A, Anveden-Berglind I, Bui CL , Kristiansen NS, Bahmanya S, McQuay LJ, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):653.
Hallas J, Margulis AV , Pottegard A, Kristiansen N, Bui CL , Krueger W, Atsma WJ, Appenteng K, Franks B, de Vogel S, D 'Silva M, Perez-Gutthann S , Arana A . Incidence of cardiovascular events in new users of overactive bladder medications in Denmark . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491.
Hallas J, Margulis AV , Pottegard A, Kaye JA, Kristiansen N, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Elevated bladder and prostate cancer rates following initiation of OAB medication: findings from the Danish Registries . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533.
Fortuny J , Kaye JA, Bui CL , Gilsenan AW , Bartsch J , Plana E , McQuay LJ, Calingaert B , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez Gutthan S , Arana A , Margulis AV . Evaluation of free-text comments to validate common cancer diagnoses in the UK CPRD . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):58.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cardiovascular risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):491-2.
Linder M, Margulis AV , Anveden-Berglind I, Bahmanyar S, Bui CL , Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S , Arana A . Cancer risk in users of antimuscarinic drugs for overactive bladder: a cohort study in the Swedish National Registers . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):533-4.
Arana A . The ENCePP methods guide . Presented at the Joint DIA/EMA Information Day on Post-Authorisation Studies (PAS); June 5, 2015. London, United Kingdom.
Arana A , Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation . Drug Saf. 2010 Jun;33(6):489-501.